The intravenous options for MRSA are generally limited to vancomycin ... inhaled and intravenous antibiotic agents. Chronic use of aerosolized antibiotics such as tobramycin or colistin, as ...

The new research, led by the University of Sheffield, reveals MRSA has a double defence mechanism against antibiotics - this new insight offers hope in treating the life-threatening superbug and ...

MRSA was once eradicated reliably by vancomycin (Vancocin AE), an antibiotic of the glycopeptide class. With time, the MRSA bacteria became resistant to vancomycin and vancomycin-resistant ...

University of Sheffield scientists have uncovered a novel mechanism enabling the superbug Methicillin Resistant Staphylococcus aureus (MRSA) to resist antibiotic treatment. This discovery reveals a ...

MRSA - or methicillin resistant staphylococcus aureus - has already become resistant to most common antibiotics, making it difficult to treat with drugs. Once it gets into the body, through wounds ...

What singles MRSA out from other bacteria is that it cannot be killed by the standard antibiotic methicillin (a synthetic form of penicillin). In the 1940s, 95 per cent of staphylococcus aureus ...

An analysis of patients with suspected sepsis at US hospitals found that antibiotic de-escalation was infrequent and varied ...

The US accounts for 80% to 90% of the total market for anti-MRSA antibiotics, so FDA approval is key to growing ceftobiprole's revenues, currently a minor part of its CHF 131 million ($137 million ...

Dr Leah Smith, a research fellow at the University of Otago, has been awarded the 2024 L’Oréal-UNESCO For Women in Science ...